Elena Aguirre

Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor–Positive, <i>ERBB2</i>-Negative Advanced Breast Cancer

Antonio Llombart‐Cussac, José Manuel Pérez-García, Meritxell Bellet et al. · JAMA Oncology · 2021 · 106 citations · Full text

Medicine, Oncology, Pharmacology +16

SEOM clinical guidelines in hereditary breast and ovarian cancer (2019)

Santiago González-Santiago, Teresa Ramón y Cajal, Elena Aguirre et al. · Clinical & Translational Oncology · 2019 · 72 citations · Full text

Life Sciences, Genetics, Oncology +17

Prevalence and Characteristics of <i>MUTYH</i> -Associated Polyposis in Patients with Multiple Adenomatous and Serrated Polyps

Carla Guarinós, Míriam Juárez, Cecilia Egoavil et al. · Clinical Cancer Research · 2014 · 66 citations · Full text

Medicine, Genetics, Oncology +17

Quality of Colonoscopy Is Associated With Adenoma Detection and Postcolonoscopy Colorectal Cancer Prevention in Lynch Syndrome

Ariadna Sánchez, Victorine H. Roos, Matilde Navarro et al. · Clinical Gastroenterology and Hepatology · 2020 · 50 citations

Medicine, Clinical Sciences, Oncology +17

PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer.

Antonio Llombart‐Cussac, José Manuel Pérez-García, Meritxell Bellet et al. · Journal of Clinical Oncology · 2020 · 48 citations

Medicine, Oncology, Pharmacology +15